Onabotulinum toxin A: a therapeutic option for refractory neurogenic detrusor overactivity and idiopathic overactive bladder

Abstract

Overactive bladder syndrome affects up to 17% of the American population and adversely impacts quality of life. Antimuscarinic agents have been the primary treatment of neurogenic detrusor overactivity and overactive bladder, but they are often ineffective or poorly tolerated. Onabotulinum toxin A for refractory cases provides an important therapeutic alternative. Indications, use, efficacy and safety data for intradetrusor injection of onabotulinum toxin A will be reviewed.